Facebook      Twitter




Inflammation in Persons Living with HIV (18HH03)

Jihad Slim, MD, and Christopher F. Saling, MD

Release Date: June 1, 2016
Expired: May 31, 2018
Activity Code: 18HH03

This content is being provided for informational purposes only.

If you have any questions about this process, please email the Center for Continuing and Outreach Education at ccoereg@ca.rutgers.edu or call CCOE Enrollment Services at (800) 227-4852.
As seen in the Summer 2016 edition of



Provided by the François-Xavier Bagnoud (FXB) Center, School of Nursing, Rutgers, The State University of New Jersey and the Center for Continuing and Outreach Education at Rutgers Biomedical and Health Sciences.


This activity is supported by an educational grant from the New Jersey Department of Health (NJDOH)—Division of HIV, STD and TB Services, through an MOA titled “Education and Training for Physicians and other Healthcare Professionals in the Diagnosis and Treatment of HIV/AIDS”.

Statement of Need

There is a complex interaction between HIV infection, inflammation, and the immune system. Antiretroviral therapy (ART) has evolved to a point where most persons living with HIV (PLWH) can achieve an undetectable viral load within 12 weeks of starting treatment. However, chronic inflammatory processes still occur even in well-controlled HIV infection. Therefore, in an effort to further improve disease outcome, methods to decrease chronic inflammation have become a new focus of research.

This activity will review the most common comorbidities encountered in PLWH and discuss their relationship to environmental and genetic risk factors, HIV-related inflammatory state, and ART.

Target Audience

This activity is designed for physicians, physician assistants, advanced practice nurses, nurses, and other health care professionals in New Jersey who are involved in the care of people infected with HIV.

Method of Participation

Participants should read the learning objectives, review the activity in its entirety, and then complete the self-assessment test, which consists of a series of multiple-choice questions. Upon completing this activity as designed and achieving a passing score of 70% or more on the self-assessment test and submitting a course evaluation, participants will receive a printable credit statement.

Learning Objectives

Upon completion of this activity, participants should be able to:

  1. Identify manifestations of inflammation in PLWH.
  2. Articulate benefits of early and continuous undetectable HIV viral load to decrease chronic inflammation.
  3. Recognize risk factors for common comorbidities in PLWH.
  4. Identify approaches to prevent and manage comorbidities and co-infection in order to control chronic inflammation.


Activity Director/Academic Advisor

Jihad Slim, MD
Medical Director, NJDOH-Division of HIV, STD and TB Services

Planning Committee

Connie Calisti-Myers, JD, Assistant Commissioner, NJDOH-Division of HIV, STD and TB Services

John Nelson, PhD, CPNP, Program Director, AETC NCRC, FXB Center, Rutgers University

Andrea Norberg, MS, RN, Executive Director, FXB Center, Rutgers University

Shobha Swaminathan, MD, Assistant Professor, Division of Infectious Diseases, Department of Medicine, Rutgers New Jersey Medical School

Michelle Thompson, Program Manager, FXB Center, Rutgers University

Macsu Hill, MPH, CHES, Program Development Specialist, FXB Center, Rutgers University

Elizabeth Ward, MSJ, Executive Director, Rutgers CCOE

Activity Authors

Jihad Slim, MD
Medical Director NJDOH Division of HIV, STD and TB Services

Christopher F. Saling, MD
Resident, Saint Michael’s Medical Center


Credit is no longer available for this activity.

Peer Review

In order to help ensure content objectivity, independence, and fair balance, and to ensure that the content is aligned with the interest of the public, CCOE has resolved all potential and real conflicts of interest through content review by a non-conflicted, qualified reviewer. This activity was peer-reviewed for relevance, accuracy of content and balance of presentation by John Nelson, PhD, CPNP.

Field Test:
This activity was field tested for time required for participation by Noa’a Shimoni, MD, MPH, Marshall Glesby, MD, MPH, Lisa A. Pittarelli, MD, FACP, Anna M. Haywood, MSN, RN, Laura Bogert, BSN, RN, and Renée Powell, BS, RN.

Disclosure Disclaimer

In accordance with the disclosure policies of Rutgers University and to conform with ACCME and FDA guidelines, individuals in a position to control the content of this educational activity are required to disclose to the activity participants: 1) the existence of any relevant financial relationship with any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients, with the exemption of non-profit or government organizations and non-health care related companies, within the past 12 months; and 2) the identification of a commercial product/device that is unlabeled for use or an investigational use of a product/ device not yet approved.

Disclosure Declarations

Jihad Slim, MD, receives grant/research support from Gilead Sciences and ViiV Healthcare. He is also a member of the Speakers Bureau for AbbVie, Bristol-Myers Squibb, Janssen Pharmaceuticals, Gilead Sciences, and Merck & Co.

Shobha Swaminathan, MD, is a member of the Advisory Board of and receives grant/research support from Gilead Sciences for HIV testing (grant provided to Rutgers University).

All other authors, planning committee members, peer reviewers and field testers have no relevant financial relationships to disclose.

Off-Label/Investigational Usage Disclosure

This activity contains information of commercial products/devices that are unlabeled for use or investigational uses of products not yet approved. It describes the investigational use of non-approved products including rosuvastatin IL-7 and Saccharomyces boulardi for anti-inflammatory therapy in PLWH.

The views expressed in this activity are those of the faculty. It should not be inferred or assumed that they are expressing the views of NJDOH – Division of HIV, STD and TB Services, any manufacturer of pharmaceuticals or devices, or Rutgers University. It should be noted that the recommendations made herein with regard to the use of therapeutic agents, varying disease states, and assessments of risk, are based upon a combination of clinical trials, current guidelines, and the clinical practice experience of the participating presenters. The drug selection and dosage information presented in this activity are believed to be accurate. However, participants are urged to consult all available data on products and procedures before using them in clinical practice.

Copyright © 2016 Rutgers University

All rights reserved including translation into other languages. No part of this activity may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, recording, or any information storage and retrieval systems, without permission in writing from Rutgers University.

Privacy Policy

To review Rutgers' privacy policy, please see: http://ccoe.rbhs.rutgers.edu/general/privacypolicy.html

Please direct CE related or technical questions to Rutgers at 973-972-4267 or email ccoe@ca.rutgers.edu.


© Copyright 2020, Rutgers, The State University of New Jersey, an equal opportunity, affirmative action institution.

Privacy Policy